Forest's Celexa Adds Warning On Dose-Dependent QT Prolongation
This article was originally published in The Pink Sheet Daily
Executive Summary
The labeling revision, which reflects the results of a thorough QT study, makes Celexa the first drug in the SSRI/SNRI class of antidepressants to include a general warning about QT interval effects.
You may also be interested in...
Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
Extensive data on immediate and extended release exenatide can be "leveraged and applied" to speed development of a once-monthly injectable, which is ready for Phase III.
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
The medullary thyroid cancer drug's Risk Evaluation and Mitigation Strategy requires mandatory enrollment and certification of prescribers and pharmacists, which should help ensure the drug is used primarily in patients with symptomatic, progressive disease.
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.